Daily source brief
Source brief: MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults
Human trial evidence that a specific NMN formulation can increase circulating NAD-related measures.
Simple answer
Human trial evidence that a specific NMN formulation can increase circulating NAD-related measures.
At a glance
What this source says
Human trial evidence that a specific NMN formulation can increase circulating NAD-related measures.
Why it matters
This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.
What it does not prove
A biomarker increase is not the same as proof of slower aging or longer lifespan.
How LHN is using it
This brief records the source in the public evidence trail and links to the original. It does not turn a paper, registry entry or regulatory document into personal medical advice. The source's design, population and stated limitations still determine what conclusions are reasonable.
Read the original source
A biomarker increase is not the same as proof of slower aging or longer lifespan.
Open Journals of Gerontology: Series ARead next
Get the weekly longevity evidence briefing.
One plain-English email on the claims, studies and regulatory updates worth knowing - without protocols, hype or miracle claims.
No protocols. No miracle claims. No spam.